meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic glioblastoma (mGB) - 2nd line (L2)
head and neck cancer squamous cell cancer (HNSCC)
immune chekpoint inhibitors
anti-PD-(L)1
avelumab based treatment
avelumab alone
durvalumab based treatment
durvalumab alone
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab plus 5FU plus platin
Immune checkpoint association
durvalumab plus tremelimumab